5 recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 5, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: new trials by email Literature Review of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials Research Report on Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 24 | 2026-07-15 | 2026-07-10 |
| Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis | Phase 1 | Recruiting | Kite, A Gilead Company | 57 | 2026-04-10 | 2026-10-19 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders | Phase 1 | Recruiting | TG Therapeutics, Inc. | 100 | 2025-05-06 | 2026-10-27 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP KINE-101 - CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 1 | Completed | Kine Sciences Co., Ltd. | 9 | 2024-08-27 | 2026-01-20 |
| IVIG vs SCIG in CIDP Intravenous immune globulin G, Subcutaneous immune globulin G - CIDP, Immunoglobulin Deficiency | Phase 1 | Recruiting | Rutgers, The State University of New Jersey | 20 | 2022-09-11 | 2025-12-11 |
| A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant - Healthy, Primary Immune Thrombocytopenia | Phase 1 | Terminated | Pfizer | 58 | 2017-07-17 | 2024-07-05 |
Myasthenia Gravis (4) · Multiple Sclerosis (3) · Neuromyelitis Optica (3) · Myositis (2) · Agammaglobulinemia (1) · Autoimmune Diseases of the Nervous System (1) · Obesity (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Autoimmune Diseases (8) · Chronic Disease (8) · Demyelinating Diseases (8) · Disease Attributes (8) · Immune System Diseases (8) · Nervous System Diseases (8) · Neuromuscular Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Peripheral Nervous System Diseases (8) · Polyneuropathies (8) · Polyradiculoneuropathy (8) · Autoimmune Diseases of the Nervous System (7) · Demyelinating Autoimmune Diseases, CNS (4) · Neoplasms (4)
Cyclophosphamide (2) · fludarabine (2) · Hizentra (1) · Immunoglobulins, Intravenous (1)
Kine Sciences Co., Ltd. (1) · Kite, A Gilead Company (1) · Pfizer (1) · Rutgers, The State University of New Jersey (1) · TG Therapeutics, Inc. (1) · Tianjin Medical University General Hospital (1) · Tongji Hospital (1) · Zhongming Qiu (1)
United States (4) · China (2) · Australia (1) · Belgium (1) · Canada (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Chuan Qin (1) · Daishi Tian (1) · Hanna Park (1) · Luigi Brunetti, PhD (1) · Qiang Liu, M.D.,Ph.D (1)
2018 (1)